PMID- 26581165
OWN - NLM
STAT- MEDLINE
DCOM- 20170410
LR  - 20210331
IS  - 1440-0960 (Electronic)
IS  - 0004-8380 (Linking)
VI  - 57
IP  - 2
DP  - 2016 May
TI  - IVIG therapy in pemphigus vulgaris has corticosteroid-sparing and 
      immunomodulatory effects.
PG  - 141-4
LID - 10.1111/ajd.12422 [doi]
AB  - BACKGROUND: Intravenous immunoglobulin (IVIG) is a biological agent composed of 
      polyclonal antibodies prepared from a large cohort of human plasma pools. IVIG is 
      increasingly used for the treatment of various antibody-mediated diseases, 
      including pemphigus vulgaris (PV). OBJECTIVE: The aim of the study was to 
      evaluate the benefit and safety profiles of high dose IVIG therapy in PV patients 
      determined by clinical remission, corticosteroid-sparing and immunomodulatory 
      effects, and adverse events at 12 months' follow up. METHODS: Ten PV patients 
      underwent 3-8 monthly cycles of IVIG therapy at a dose of 2 g/kg per cycle. The 
      pemphigus disease area index (PDAI) score, direct immunofluorescence (DIF), 
      indirect immunofluorescence (IIF), and corticosteroid dosage were evaluated 
      before IVIG therapy, after each cycle, and at 6 and 12 months' follow up. 
      RESULTS: The baseline PDAI score was 75.70 +/- 21.0 and baseline prednisone dosage 
      was 201.60 +/- 71.7 mg/day. The PDAI score reduction of 98% was achieved at 12 
      months' follow up and a corticosteroid dose reduction of 90% corresponded to 
      clinical improvement. The decrease in both values was statistically significant 
      (P = 0.002, respectively). At 12 months' follow up, seven patients were shown to 
      be negative on IIF, of whom three proved to be negative on DIF. Adverse events 
      were mild and transient and did not require the cessation of IVIG therapy. 
      CONCLUSION: IVIG induced long-term clinical remission, while displaying a 
      corticocorticosteroid-sparing effect and evoking a long-standing immunomodulatory 
      effect in PV patients. The safety profile of IVIG therapy was assessed as good.
CI  - (c) 2015 The Australasian College of Dermatologists.
FAU - Svecova, Danka
AU  - Svecova D
AD  - Department of Dermatovenerology, Faculty of Medicine, Comenius University, 
      University Hospital, Bratislava, Slovakia.
LA  - eng
PT  - Journal Article
DEP - 20151118
PL  - Australia
TA  - Australas J Dermatol
JT  - The Australasian journal of dermatology
JID - 0135232
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Immunoglobulins, Intravenous)
RN  - VB0R961HZT (Prednisone)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Inflammatory Agents/administration & dosage
MH  - Female
MH  - Humans
MH  - Immunoglobulins, Intravenous/administration & dosage/adverse effects/*therapeutic 
      use
MH  - Immunomodulation/*drug effects
MH  - Male
MH  - Middle Aged
MH  - Pemphigus/*drug therapy
MH  - Prednisone/administration & dosage
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - autoimmune bullous disease
OT  - corticosteroid-sparing effect
OT  - immunomodulatory effect
OT  - intravenous immunoglobulin (IVIG)
OT  - pemphigus vulgaris
OT  - safety profile
EDAT- 2015/11/20 06:00
MHDA- 2017/04/11 06:00
CRDT- 2015/11/20 06:00
PHST- 2015/05/14 00:00 [received]
PHST- 2015/10/07 00:00 [accepted]
PHST- 2015/11/20 06:00 [entrez]
PHST- 2015/11/20 06:00 [pubmed]
PHST- 2017/04/11 06:00 [medline]
AID - 10.1111/ajd.12422 [doi]
PST - ppublish
SO  - Australas J Dermatol. 2016 May;57(2):141-4. doi: 10.1111/ajd.12422. Epub 2015 Nov 
      18.